1. Grove WR, Fortner CL, Wiernik PH: Review of amsacrine, an investigational antineoplastic agent. Clin Pharm 1:320?326, 1982
2. Grove WR, Delap LW, Grillo-Lopez AJ: CI-921: An analog of amsacrine with experimental activity against solid tumors. Invest New Drugs 4:113?118, 1986
3. Baguley BC, Denny WA, Atwell GJ, Finlay GJ, Rewcastle GW, Twigden SJ, Wilson WR: Synthesis, antitumor activity, and DNA binding properties of a new derivative of amsacrine, N-5-dimethyl-9-[(2-methoxy-4-methylsulfonylamino) phenylamino]-4-acridinecarboxamide. Cancer Res 44:3245?3251, 1984
4. Robert F, Mignucci M, Grove WR, Javier J, Asmar S, GrilloLopez AJ: Phase I study of CI-921: Single dose schedule. Proc Am Soc Clin Oncol 6:26, 1987
5. Grove WR, Grillo-Lopez AJ, Robert F, Harvey V, Leiby J, Javier J, Hardy J, Grever M: Optimizing therapeutic potential of Phase I studies: coordination of three worldwide studies of CI-921. Proc Eur Cong Clin Oncol 4:287, 1987